Skip to content

Effect of different doses of esketamine on the quality of recovery from postoperative anesthesia in lumbar decompression surgery

Effect of different doses of esketamine on the quality of recovery from postoperative anesthesia in lumbar decompression surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095890
Enrollment
Unknown
Registered
2025-01-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Control group (N group) :Analgesic pump to be sufentanil 2.0µg/kg + metoclopramide 20mg + saline diluted to 100ml, analgesic pump background infusion rate of 2ml/h, self-control of a single dose of in
Intervention group1 (s1 group) :The analgesic pump was given esketamine 0.25mg/kg + sufentanil 1.5µg/kg + metoclopramide 20mg + saline diluted to 100ml.
Intervention group2 (s2 group) :The analgesic pump was given esketamine 0.5mg/kg + sufentanil 1.5µg/kg + metoclopramide 20mg + saline diluted to 100ml.
Intervention group3 (s3 group) :The analgesic pump was given esketamine 1.0mg/kg + sufentanil 1.5µg/kg + metoclopramide 20mg + saline diluted to 100ml.

Sponsors

The Second People’s Hospital of Hefei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) The patient is to undergo lumbar decompression fusion and internal fixation, ASA grade I-II; (2) Patient's age>=40 years, <=65 years; (3) Body Mass Index (BMI) 19~24 kg/m^2; (4) The patient's communication is normal and has a certain learning ability.

Exclusion criteria

Exclusion criteria: (1) Severe respiratory and circulatory diseases: such as severe coronary atherosclerosis, acute myocardial infarction, respiratory failure and other underlying diseases; (2) Nervous system diseases: such as severe cerebral hemorrhage or sequelae of cerebral infarction, hemiplegia, aphasia, etc.; (3) Mental and psychological diseases: such as schizophrenia, depression, etc.; (4) Long-term abuse of analgesics, history of chronic pain, etc.; (5) Combined with obvious abnormal liver and kidney function; (6) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale, VAS;Ramsay Sedation Scale;Dosage of sufentanil used;The end time of the operation;Heart Rate;SPO2;Mean Arterial Pressure, MAP;

Secondary

MeasureTime frame
Awakening restlessness;Postoperative Nausea and Vomiting ,PONV;Hypotension;Adverse reactions;Quality of Recovery-15" scale, QoR-15;

Countries

China

Contacts

Public ContactJunjie Liu

The Second People’s Hospital of Hefei

liujunjie1989_999@126.com+86 138 6679 0510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026